Literature DB >> 9030890

In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat.

S Delobette1, A Privat, T Maurice.   

Abstract

The beta-amyloid peptide-(25-35) fragment, but not beta-amyloid peptide-(1-28), shares with beta-amyloid protein-(1-42) the ability to self-aggregate and to induce neurotoxicity in vitro. This study examined the induction of amnesia in rats given intracerebroventricularly soluble or aggregated beta-amyloid peptide-(25-35) (5-45 nmol), or beta-amyloid peptide-(1-28) (15 nmol). Memory deficit in the water-maze test, examined 14 days after aggregated beta-amyloid peptide-(25-35) injection, was more pronounced than with soluble beta-amyloid peptide-(25-35). beta-Amyloid peptide-(1-28) only affected retention. These results confirm the direct amnesic properties of beta-amyloid peptides in the rat brain and showed that prior peptide aggregation markedly facilitates the appearance of amnesia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030890     DOI: 10.1016/s0014-2999(96)00922-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  32 in total

1.  Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo.

Authors:  V V Trubetskaya; M Yu Stepanichev; M V Onufriev; N A Lazareva; V A Markevich; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2003-02

2.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

3.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

4.  Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze.

Authors:  M Yu Stepanichev; Yu V Moiseeva; N A Lazareva; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2005-06

5.  Studies of the effects of central administration of beta-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory.

Authors:  M Yu Stepanichev; I M Zdobnova; I I Zarubenko; N A Lazareva; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2006-01

6.  Effects of beta-amyloid (25-35) on learning in the common snail.

Authors:  T A Korshunova; E I Samarova; N I Bravarenko; P M Balaban
Journal:  Neurosci Behav Physiol       Date:  2008-05

7.  Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25-35 in rats.

Authors:  Yeye Zhuo; Haibiao Guo; Yufang Cheng; Chuang Wang; Canmao Wang; Jingang Wu; Zhengqiang Zou; Danna Gan; Yiwen Li; Jiangping Xu
Journal:  Metab Brain Dis       Date:  2016-02-27       Impact factor: 3.584

8.  The modulatory role of phloretin in Aβ25-35 induced sporadic Alzheimer's disease in rat model.

Authors:  Priya J Ghumatkar; Sachin P Patil; Vaibhavi Peshattiwar; Tushara Vijaykumar; Vikas Dighe; Geeta Vanage; Sadhana Sathaye
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-28       Impact factor: 3.000

9.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

Review 10.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.